PRESS RELEASES

Found 251 Results
Page 24 of 26

BioAlliance Pharma provides updates on its major achievements and reports 2013 consolidated financial results


2013: Significant progress on key strategic programs • Livatag® phase III (ReLive): European expansion and authorization from the FDA to […]

Tags:

02/27/2014


Strengthening and extension of the industrial protection of Livatag® until 2031 – First delivery of a new European patent


BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products, announced today […]

02/18/2014


BioAlliance Pharma’s partner, Sosei, announces a partnership with FUJIFILM Pharma for commercialization rights for Loramyc® in Japan


Paris, February 4, 2014 – BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan […]

02/04/2014


FDA grants Validive® (clonidine Lauriad®) with a Fast Track Designation for the prevention and treatment of oral mucositis induced by anticancer treatments


BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology, announced today that […]

01/23/2014


Quarterly information as of September 30, 2013


BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of Orphan Oncology Products and to […]

Tags:

11/14/2013


Key milestones and consolidated accounts First semester 2013


Grant of the Marketing Authorization for Sitavig® in the US Strong achievements in clinical trials with Livatag® (phase III) and […]

Tags:

09/19/2013


Bioalliance Pharma updates on major achievements of 2012 and publishes its 2012 consolidated financial statements and income for Q1 2013


Successful key milestones reached on all orphan oncology clinical programs First registration of Sitavig granted in European countries Oravig licensing […]

Tags:

04/15/2013


Quarterly information as of September 30, 2012 • A dynamic progression of BioAlliance Pharma portfolio Orphan


• Orphan Oncology Products: recruitment of the first patients in Phase III clinical trial with Livatag® in primary liver cancer […]

Tags:

11/14/2012


Key milestones and consolidated accounts for the first semester of 2012


• Key achievements in the clinical development programs and especially: – Livatag®: Phase III study opened in France in June […]

Tags:

09/13/2012


Full-year financial results for 2011 • Q1 2012 Consolidated turnover


• A growth strategy focused on orphan oncology products • Promising products in advanced development • Reinforced cash reserves at […]

Tags:

04/17/2012


Page 24 of 26

Last updated on